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Summary, conclusions and further remarks
In the Netherlands, breast cancer is the mostfrequent ype of cancer
in women. l t  is character ized by a wide spectrum of c l in ical  behavior
and is accompanied by a large var iat ion in pat ient character ist ics.
The large amount of diagnost ic possibi l i t ies and treatment opt ions
are reflected by the multidisciplinary approach of these patients.
Chemotherapy is one of the treatment modalities, as breast cancer
is considered by many as a systemic illness.
Atfirst sight it seems that there is a clear difference between adjuvant
chemotherapy after a curative primary treatment and palliative
chemotherapy for metastatic disease. However, patients with a high
number of positive axillary lymph nodes have an unfavorable
prognosis and a poor chance of survival ,  despite adjuvant chemo-
therapy. With high dose chemotherapy in combinat ion with
autologous bone marrow transplantation (ABMT) or peripheral
blood stem cells transplantation (PSCT) it seems possible for a subset
of these patients to reach long term survival and possibly even cure.
In this thesis a number of tumor and pat ient character ist ics,  t reat-
ment options with emphasis on chemotherapy and several aspects
of qualityof life and long term toxicities are discussed. The optimization
of standard ad juvant CMF (cyclophosphamide, methotrexate and 5-
fluorouracil) with the help of a growth factor is described, but the
main part  of  the thesis concerns the experience with high dose
chemotherapy in combinat ion with ABMT and/or PSCT and growth
factors.
ln chapter 1 a review is given with respect o the question how to
fit the appropriate treatment to each breast cancer patient. Tumor
and patient characteristics should be the basis, on which treatment
decisions are taken.
Different reatment options are discussed: standard, new and high
dose chemotherapy in primary, metastatic and special forms of
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breast  cancer and for  specia l  pat ient  groups.  The dose and dose-
intensi ty  of  the chemotherapy appear to be important  wi th respect
to the ef f icacy of  the t reatment  in  the adjuvant  as wel l  as in  the
metastat ic  set t ing.  The ro le of  the anthracycl ines as wel l  as new
drugs  such  as  t he  taxanes  a re  d i scussed .  H igh  dose  chemothe rapy
wi th a tenfo ld h igher  dose compared to s tandard is  feasib le because
of  the support  oÍ  growth factors,  ABMT and/or  PSCT. However,
randomized studies wi th respect  o h igh dose chemotherapy are not
ye t  ava i l ab le  and  h igh  dose  chemothe rapy  shou ld  t he re fo re  s t i l l  be
considered an exoer imenta l  t reatment .
Aspects of  q ual i ty  of  l i fe  and long term tox ic i t ies,  such as card iotox ic i ty
a re  i nc reas ing l y  s tud ied  and  recogn i zed  as  h igh l y  impor tan t  i n  t he
choice of  t reatment .
In chapter  2 a cyto logical  scor ing system is  evaluated wi th the
intent ion to use i t  as a prog nost ic  factor .  The h is to log ica l  grade of  the
tumor  i s  a  we l l  known  and  rep roduc ib le  me thod ,  used  to  p red i c t
prognosis.
As cyto logy is  an ear l ier  and easier  d iagnost ic  procedure compared
to  h i s to logy ,  t he  cy to log i ca l sco re  i seva lua ted  i n  t h i s  chap te r  on  the
potent ia l  to  predict  the h is to logical  grade.
ln conclus ion,  the cyto logical  scor ing system we have tested re l iab ly
predicts  the presence of  wel l  or  moderate ly  h is to logical ly  graded
tumors,  as shown by 8oo/o concordance (95o/o conf idence interval
63-920/o)  between a low cyto logy score and low his to logy grade.
However,  the number of  h igh grade tumors is  overest imated,  as
shown by only 45o/o concordance (95olo conf idence interval  23-
680lo)  between a h igh cyto logy score and h igh h is to logy grade.
Cy to log i ca l  g rad ing  d id  no t  have  i ndependen t  p rognos t i c  va lue  a t
a median fo l low up of  B years.
In chapter  3 a method is  s tudied,  which can detect  low numbers of
ep i t he l i a l  t umor  ce l l s  i n  pe r i phe ra l  b l ood  and  bone  mar row .  The
signi f icance of  micrometastas is  detect ion in  b lood and bone marrow
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Because i t is l ikely that tumor cel ls are reinfused to the pat ient with
the autograft  when using the support  of  ABMT and/or PSCT for hig h
dose chemotherapy, the quant i tat ive detect ion of tumor cel ls in the
graft  is of  c l in ical  interest.  With the possibi l i ty o detect low numbers
of tumor cel ls i t  is also possible to evaluate the effect of  techniques,
who e l im ina te  tumor  ce l l s  f rom b lood or  bone mar row ( the  so  ca l led
'purg ing ' ) .
To  de tec t  low numbers  o f  ep i the l ia l  tumor  ce l l s ,  an  ep i the l ia l
g lycoprotein (EC P-2) based, quantitative nested, reverse transcriptase-
polymerase chain react ion (RT-PCR) assay is evaluated in this chapter.
In this study, a considerable range in ECP-2 transcr ipt  levels was
found in di f ferent carcinoma cel l  l ines and normal bone marrow. An
unexpected low expression of ECP-2 was found in peripheral  blood
mononuc lear  ce l l s .  The express ion  i  normal  b lood prevents  re l iab le
es t imat ions  o f  low number  o f  ep i the l ia l  tumor  ce l l s  in  c l in ica l
samples, as the detect ion level of  the highest ECP-2 expressing
carcinoma cel ls added to peripheral  blood was not better than one
tumor  ce l l  in  2  x  I0a  normal  ce l l s .
Chapter 4 reviews the treatment in elder ly pat ients,  because age is
a pat ient character ist ic direct ly or indirect ly inf luencing the breast
cancer treatment in cl in ical  oract ice.
The incidence of breast cancer is increasing with age; 30-50o/o of the
pat ients are over 65 years. This large group of pat ients receives less
screening and treatment compared to younger pat ients.  How to
treat elder ly pat ients should not be based on age, but should be
balanced with relat ive and absolute contraindicat ions in patíents
who might  a lso  have o ther  age re la ted  iseases .
The f i rst  choice for ad juvant treatment is of ten hormonal,  as in other
postmenopausal pat ients.  In pal l iat ive treatment hormonal therapy
wil l  be f i rst  choice as wel l ,  but there may be some indicat ions for the
use of chemotherapy, such as i rresponsiveness to hormonal therapy,
estrogen receptor-negative tu mors or in prog ressive or life-th reaten in g
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disease.  Di f ferent  chemotherapeut ic  possib i l i t ies are descr ibed,  fo-
cus ing  on  pha rmacodynamics ,  pha rmacok ine t i cs  and  d rug  i n te r -
ac t i ons  i n  e lde r l y  Pa t i en t s .
In chapter  5 a c l in ica l  s tudy is  presented in which the growth factor
granulocyte-colony st imulat ing factor  (c-CSF) is  used wi th the goal
to reduce the hematological  tox ic i ty ,  opt imiz ing the dose and dose
intensi ty  of  s tandard adjuvant  CMF chemotherapy.
This s tudy was star ted,  because tota l  dose and dose intensi ty  are
important  means to improve d isease f  ree surv iva l  (DFS) and overal l
surv iva l  (os)  and hematological  tox ic i ty ,  main ly  consist ing of  in-
adequate leukocyte recovery,  is  the most  important  cause of  dose
and  dose  i n tens i t y  reduc t i on '  Bonadonna  e t  a l .  have  shown  i n  a
ret rospect ive analys is  that  the ef f icacy of  the rout inely  used adjuvant
CMF i s  dependen t  on  the  to ta l  dose  ac tua l l y  admin i s te red '  A
cumulat ive of  65-850/o f  the pro jected dose was associated wi th a
worse DFS, compared to a del ivered dose over  85o/o.  For  a dose under
650lo the DFS was s imi lar  to  contro ls ,  who received no adiuvant
t reatment .  In  our  s tudy the use of  C-CSF resul ted in  adequate
hematological  recovery in  B3olo of  the fo l lowing chemotherapy
cycles.  In  pat ients wi th inadequate leukocyte recovery at  the star t  o f
a p lanned chemotherapy cyc le,  the dose intensi ty  of  the pat ients
who received C-CSF was h igher  compared to those who received no
C-CSF. l t  was however not  possib le to reach the maximum dose
intensi ty  comparable to the pat ients wi th spontaneous adequate
hematological  recovery.  A negat ive impact  of  radiotherapy on
hematological  recovery of  leukocytes and p late lets  was found in th is
study.
In chapter  6 a rev iew is  g iven addressing some aspects re levant  to
the adminis t rat ion of  h igh dose chemotherapy.
This ar t ic le  d iscusses the opt imizat ion of  bone marrow recovery af ter
h igh dose chemotherapy by the addi t ion of  PSCT and growth factors
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The pros and cons and d i f ferent  opt ions of  PSCT are rev iewed.  A
per ipheral  b lood stem cel l  is  harvested af ter  mobi l izat ion wi th a
growth factor  a lone,  chemotherapy a lone or  af ter  chemotherapy
fo l lowed by a growth factor ,  most ly  C-CSF or  CM-CSF, but  com-
binat ions of  var ious growth factors inc luding the in ter leukins 3 and
6 are of  potent ia l  advantage wi th regard to the qual i ty  of  the graf t .
I t  is  concluded that  h igh dose chemotherapy in  sol id  tumors is
nowadays a feasib le t reatment  due to the reduct ion oÍ  hematological
compl icat ions such as in fect ions and b leeding due to PSCT, ABMT
and the improved support  by growth factors .
The re levance of  tumor cel ls  in  re infused b lood stem cel ls  or  bone
marrow is  as yet  unl<nown. As i t  is  thought  that  only  a low number
of  c i rcu lat ing tumor cel ls  are 'successfu l '  in  establ ish ing metastat ic
colonies,  techniques such as immunocytochemist ry  and PCR are
be ing  deve loped .  Seve ra l  ' pu rg ing '  t echn iques  to  e l im ina te  t umor
cel ls  f rom per ipheral  b lood stem cel ls  and bone marrow, such as
lec t i n  sepa ra t i on ,  immunosepa ra t i on  and  immunomagne t i c  beads -
separat ion in  combinat ion wi th tox ins or  chemotherapy are d iscussed.
In chapter  7 the ef f icacy and tox ic i ty  of  an in tensive induct ion
regimen as preparat ion for  h igh dose chemotherapy was studieo.
Pat ients wi th local ly  advanced or  metastat ic  breast  cancer were
treated 4 weekly wi th an regimen consist ing of  6 cyc les methotrexate,
5- f luorouraci l  a l ternat ing wi th 6 cyc les doxorubin,  v incr is t ine and
orednisone.
ln conclus ion,  the induct ion regimen is  ef fect ive,  as i t  carr ies 77o/o
overall responses wilh 43o/o complete responses and the toxicity
prof i le  is  acceptable,  except  for  the pat ients wi th l iver  metastases,  as
thei r  inc idence of  leucopenic fever  was 32o/o and cerebel lar  5-
f luorouraci l  neurotox ic i ty  amounted lo 25o/o.
Chapter  8 descr ibes the use of  adjuvant  h igh dose chemotherapy in
combinat ion of  ABMT for  breast  cancer pat ients,  who have a poor
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prognosis based on the presence of 5 or more positive axillary lymph
nodes. After pretreatment with the induction regimen as described
in chapter Z, the high dose chemotherapy consisted of a combina-
t ion of ei ther cyclophosphamide+etoposide or mitoxantrone
+thiotepa.
The conclusion of this study is that the regimen appears to be
effective, as the 5-year predicted DFS is 84olo. However, the treat-
ment is toxic, beca u se 2 out of 24 patients died d ue to the treatment.
It is stil l impossible to draw definite conclusions on the superiority of
high dose chemotherapy, as it is necessary to await randomized
studies comparing standard with high dose ad juvant chemotherapy.
In chapter 9 the effect of PSCT in addition to ABMT and a growth
factor in the adjuvant treatment with high dose chemotherapy for
breast cancer patients with 5 or more positive axillary lymph nodes
is described. The addition of PSCT to ABMT and a growth factor
improves the rate of hematopoietic reconstitution with a decrease of
4.5 days in durat ion of neutropenia ( leukocytes under 0.5 x 10' / l
decreased from 14.5 days to 1 0 days) and of 9 days in thrombopenia
(platelets under 20 x 10ell decreased from 25 to 1 6 days).
The addit ion of PSCT also diminishes hematopoiet ic compl icat ions
such as infections and reduces the number of platelet- and blood
transfusions and days of hospitalization. With the addition of PSCT,
the safety of high dose treatment has increased, although it is stil l
considered an experimental treatment, the toxicity of it has de-
creased substantial.
In chapter 10 attention is paid to the occurrence of long term
cardiotoxici ty as one of the late compl icat ions of high dose
chemotherapy in combination with radiotherapy.
With the improvement of the efficacy of the treatment, especially in
the adjuvant setting leading to more long term survivors, it is
relevant o pay attention to aspects of quality of life and long term
complicat ions.
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In a group of 86 patients, treated with high dose chemotherapy and
radiotherapy, the estimated 7-years percentage of clinical and
subcf in ical cardiac dysf unction is 22o/o (95olo conf idence interval 5-
39o/o).
The observed cardiac dysfunction in this study concerns 6 patients.
One patient (1olo) died three months after high dose chemotherapy
of subacute cardiac failure. One patient who was treated exceptionally
with two transplantations, has serious congestive heart failure.
Minor subcl inical  cardiac dysfunct ion, as measured on the
radionuclide angiography measuring the left ventricular ejection
fraction (LVEF), was found in 4 out of 26 evaluated patients.
In conclusion, long term cardiotoxicity should receive more atten-
tion, but thus far it does not hamper the use of high dose chemo-
therapy in patients who will otherwise have a poor chance of
survival.
Further remarks
Breast cancer is a considerable medical, emotional and economical
problem. lt is at life-time observation diagnosed at 1 out of 10
women in the Netherlands.
Due to the heterogeneity of the tumor and the patients the clinical
course is very variable. lt is important to make a treatment tailored
to the tumor, but also to patient characteristics. The improvement
in breast cancer prognosis appears less impressive compared to
other types of cancer, such as testicular carcinoma and the
hematological malignancies, but in breast cancer progress is stil l
ongoing in early detection, screening, recognition of hereditary
factors and more effective chemotherapy.
The introduction of adjuvant chemotherapy by Nissen-Meyer et al.
from Norway by cyclophosphamide monotherapy in 1965 and of
CMF in 1973 by Bonadonna et al. from Milan, which is at present a
standard treatment, has given an absolute improvement in 10-year
OS of approximately 10olo. The profit in survival, due to adjuvant
chemothe rapy ,  depends  on  the  number  o f  pos i t i ve  ax i l l a r y  l ymph
nodes .  An th racyc l i ne -con ta in ing  schedu les ,  i n t roduced  i n  t he  e igh t -
i es ,  ca r r y  an  improved  su rv i va l  ove r  CMF in  t he  case  o f  4 - . l 0  pos i t i ve
ax i l l a r y  l ymph  nodes .  I n  t he  ad luvan t  s i t ua t i on ,  t he  p lace  o f  new
drugs  such  as  t he  taxanes  s t i l l  have  to  be  de f i ned .  The  su rv i va l  ga ins
achieved wi th chemotherapy in  the t reatment  of  metastat ic  d isease
is modest  and cure is  rare ly  obta ined.
The  use  o f  h i gh  dose  chemothe rapy  suppo r ted  by  ABMT and /o r
PSCT wi th g rowth factors is  the subject  of  extensive research over  the
las t yea rs .  H igh  dose  t rea tmen t  i s  nowadays  a  f eas ib le  t r ea tmen t  w i t h
a  reduced  number  o f  hema to log i ca l  comp l i ca t i ons  such  as  i n f  ec t i ons
and  b leed ings  as  a  resu l t  o f  ABMT,  PSCT and  the  improved  suppo r t
wi th growth factors.  St i l l  too l i t t le  is  known about  the qual i ty  of  l i fe
and  the  l ong  te rm tox i c i t y  i nhe ren t to  t h i s  t r ea tmen t .  The  resu l t s  o f
non-randomized studies wi th h igh dose chemotherapy in  the adjuvant
s i t ua t i on  a re  p rom is ing ,  bu t  t he  resu l t s  o f  t he  i n  t he  ea r l y  n ine t i es
s ta r ted  randomized  s tud ies  have  to  be  awa i ted .  W i th  t he  use  o f  h i gh
dose  chemothe rapy  i t  seems  poss ib le  f o r  a  sma l l  subg roup  o f
pat ients wi th metastat ic  d isease to achieve long term surv iva l  and
rnaybe  even  cu re ,  bu t  i n  t h i s  s i t ua t i on  i t  i s  necessa ry  t o  awa i t f u r t he r
randomized  s tud ies .
The  impor tance  o f  h i gh  dose  chemothe rapy  we igh ing  e f f i cacy
aga ins t  ox i c i t y  w i l l  no t  be  c la r i f  i ed  be fo re  t he  21  "  cen tu ry .  To  ach ieve
f u r t h e r  i m p r o v e m e n t s  i n  t h e  f u t u r e ,  a  p r o t o c o l l i z e d  a n d
mu l t i d i sc ip l i na ry  hand l i ng  o f  b reas t  ca rc inoma i s  necessa ry ,  t r ea t i ng
as much as possib le of  these pat ients in  randomized t r ia ls  as a
p r imary  goa l ,  i n  o rde r  t o  reach  va l i d  conc lus ions  abou t  t he  va lue  o f
t hese  i n tens i ve  and  exoens i ve  t r ea tmen t  moda l i t i es .
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